USPTO Patent Granted for Lipid Nanoparticle mRNA Delivery

ChangeBridge: Patent Grants - Pharma (A61K)

Published March 24th, 2026

Detected March 25th, 2026

Summary

The USPTO has granted a patent (US12582611B2) to ReCode Therapeutics, Inc. for lipid nanoparticle compositions and methods for delivering mRNA encoding the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) protein to lung cells. The patent focuses on treating or preventing cystic fibrosis.

View original document View source feed page

What changed

The United States Patent and Trademark Office (USPTO) has granted patent US12582611B2 to ReCode Therapeutics, Inc. This patent covers methods for delivering lipid nanoparticles (LNPs) containing mRNA for the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) protein to lung cells of subjects suffering from or at risk for cystic fibrosis. The claimed methods involve aerosolizing a liquid pharmaceutical composition and administering it to the subject.

This patent grant is a routine event in the pharmaceutical R&D lifecycle and does not impose new regulatory obligations on other entities. However, it signifies a new intellectual property asset for ReCode Therapeutics in the field of mRNA delivery for genetic diseases. Compliance officers in the pharmaceutical sector should note this development as it pertains to novel therapeutic delivery systems.

Source document (simplified)

← USPTO Patent Grants

Lipid nanoparticle compositions and uses thereof

Grant US12582611B2 Kind: B2 Mar 24, 2026

Assignee

ReCode Therapeutics, Inc.

Inventors

Mirko Hennig, Ali Ahmed Alfaifi, Sakya Sing Mohapatra, Daniella Ishimaru, Vladimir Grigor'evich Kharitonov, Julia Jung-un Baek, Shuang Li, David J. Lockhart, Brandon A. Wustman, Yufeng Wang, Joseph S. Cefalu

Abstract

Provided are methods for delivering lipid nanoparticles (LNPs) to a lung cell of a subject suffering from or at risk for cystic fibrosis (CF), wherein the method comprises nebulizing a liquid pharmaceutical composition to generate an aerosolized pharmaceutical composition, and administering the aerosolized pharmaceutical composition to the subject, wherein the LNPs comprise mRNA encoding a Cystic Fibrosis Transmembrane conductance Regulator (CFTR) protein.